- Home
- TDC vs SUPN Comparison
TDC vs SUPN Comparison
Compare TDC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | SUPN |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2007 | 2010 |
Fundamental Metrics
Financial Performance| Metric | TDC | SUPN |
|---|---|---|
| Price | $33.50 | $41.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $34.00 | ★ $60.50 |
| AVG Volume (30 Days) | ★ 1.7M | 992.0K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,156,000,000.00 | $392,755,000.00 |
| Revenue This Year | N/A | $23.01 |
| Revenue Next Year | $1.31 | $15.28 |
| P/E Ratio | $8.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.54 | $37.54 |
| 52 Week High | $41.78 | $59.68 |
Technical Indicators
Market Signals| Indicator | TDC | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 53.58 |
| Support Level | $26.16 | $41.86 |
| Resistance Level | $34.72 | $51.59 |
| Average True Range (ATR) | 1.19 | 2.13 |
| MACD | 0.11 | 0.24 |
| Stochastic Oscillator | 72.85 | 72.38 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.